Toronto, Ontario / ACCESSWIRE / March 25, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today the expansion of its engineering team to develop and commercialize its next generation of smart medical laser technologies. This highly trained engineering team will be instrumental in developing Theralase products to eliminate pain and heal tissue, a $100 Billion industry in the US and to destroy cancer, a $77 Billion industry in the US.
The first of these cutting-edge technologies under development is the patented TLC-2000, a technology that eliminates pain by automatically adjusting its laser parameters in direct relation to a patient's condition and their physical characteristics allowing the delivery of an optimized laser treatment, specific to a particular patient, each and every time. This dramatic advancement in pain medicine will allow much more effective patient specific treatments than currently available and also provide valuable treatment feedback information to the practitioner to further enhance the effectiveness of their patient's treatments. The second cutting-edge technology under development is the TLC-3000 anti-cancer medical laser, a patient specific cancer solution, which is able to deliver a specific dose of laser light through fibre optic bundles directly to cancerous tissues. The technology will be specifically designed to destroy tumours, wherever they may reside in the body, by activating patented Photo Dynamic Compounds (PDCs), already previously disclosed by the Company to be extremely effective in the destruction of cancer.
The newly expanded engineering team, managed by Wayne Embree, a senior engineering manager, who has been involved in leading engineering teams in the design and development of complex electronic technologies over the past 38 years. His team consists of 5 full time and 4 consultant engineering personnel, who are all resident experts in their respective fields of hardware, software, firmware and radio frequency communication design.
Mr. Embree, VP Engineering for Theralase, stated, "I am excited to join Theralase and be associated with some of the leading minds in engineering, chemistry, biology, physics and medicine to develop the next generation of medical laser technology. The technology they have amassed to date is ground breaking and with its commercialization in the next few years, they will undoubtedly introduce to main stream medicine truly disruptive technology, which will have a dramatic effect on the way medicine is practiced for years to come."
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated that, "Wayne's strong engineering background coupled with my in-depth scientific and medical knowledge in how laser light interacts at the molecular, cellular and tissue levels in the human body, will bring a whole new platform of cutting-edge laser technologies to the forefront in the next few years."
Roger Dumoulin-White, President and CEO of Theralase stated that, "I am delighted that Wayne has joined the Theralase management team and am confident in his ability to commercialize the next generation medical laser technologies. His skill set will be an asset to the corporation as we launch these disruptive technologies, allowing the Company an ability to significantly increase its revenues."
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in eliminating pain and destroying cancer. Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint injuries. Theralase is actively developing patented technology that is able to target and destroy cancers, bacteria and viruses when light activated.
Additional information is available at www.theralase.com and www.sedar.com .
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO
416-699-LASE (5273) ext. 225
SOURCE: Theralase Technologies Inc.